{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:23:58Z","timestamp":1787847838943,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"\n Purpose:<\/jats:title>\n The aim of this study was to evaluate tumor control of OSSN with topical IFN\u03b12b alone based on tumor configuration (flat versus (vs.) dome-shaped).<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Retrospective, nonrandomized, interventional cohort study on 64 consecutive tumors in 63 patients with OSSN treated with topical IFN\u03b12b. Topical IFN\u03b12b (1 million international units\/cc) was compounded and provided by the Thomas Jefferson University Hospital Pharmacy to be refrigerated and applied 4 times daily until biomicroscopic evidence of tumor resolution was observed.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The tumor configuration was flat (\n n<\/jats:italic>\n = 15, 23%) or dome-shaped (\n n<\/jats:italic>\n = 49, 77%). A comparison (flat vs. dome-shaped) revealed dome-shaped with older mean patient age at presentation (62 vs. 70 years,\n P<\/jats:italic>\n = 0.04), greater patient history of smoking (13% vs. 42%,\n P<\/jats:italic>\n = 0.04), greater corneal involvement (7% vs. 82%,\n P<\/jats:italic>\n < 0.001), larger mean basal diameter (5.5 vs. 12.4 mm,\n P<\/jats:italic>\n = 0.001) and mean thickness (1.9 vs. 4.3,\n P<\/jats:italic>\n = 0.002), and longer mean duration IFN\u03b12b therapy (3.7 vs. 6.3 months,\n P<\/jats:italic>\n = 0.002). There was no difference in mean follow-up time (22.2 vs 23.1 months) or time to complete response (5.0 vs. 6.1 months). There was no difference in achievement of complete tumor control with IFN\u03b12b alone (93% vs. 96%). There were no cases with metastasis or death.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Topical IFN\u03b12b alone shows excellent overall tumor control of 95% with no difference in efficacy based on tumor configuration.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1665_20","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T05:35:03Z","timestamp":1613540103000},"page":"563-567","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b"],"prefix":"10.4103","volume":"69","author":[{"given":"Carol L","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru B","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sefy A","family":"Paulose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Yaghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A","family":"Dalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20240828","first-page":"254","article-title":"Incidence of squamous-cell carcinoma of the conjunctiva and other eye cancers in the NIH-AARP Diet and Health Study","volume":"6","author":"Emmanuel","year":"2012","journal-title":"Ecancermedicalscience"},{"key":"R2-18-20240828","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/17469899.2017.1263567","article-title":"Diagnosis and medical management of ocular surface squamous neoplasia","volume":"12","author":"Sayed-Ahmed","year":"2017","journal-title":"Expert Rev Ophthalmol"},{"key":"R3-18-20240828","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40123-018-0140-z","article-title":"Clinical management of ocular surface squamous neoplasia: A review of the current evidence","volume":"7","author":"Cincinelli","year":"2018","journal-title":"Ophthalmol Ther"},{"key":"R4-18-20240828","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ophtha.2013.11.017","article-title":"Surgical versus medical treatment of ocular surface squamous neoplasia: A comparison of recurrences and complications","volume":"121","author":"Nanji","year":"2014","journal-title":"Ophthalmology"},{"key":"R5-18-20240828","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ophtha.2015.10.043","article-title":"Surgical versus medical treatment of ocular surface squamous neoplasia: A cost comparison","volume":"123","author":"Moon","year":"2016","journal-title":"Ophthalmology"},{"key":"R7-18-20240828","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2016.09.034","article-title":"Conjunctival tumors in 5002 cases. Comparative analysis of benign versus malignant counterparts. The 2016 James D. Allen lecture","volume":"173","author":"Shields","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R8-18-20240828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archophthalmol.2011.385","article-title":"Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: Outcomes based on the American Joint Committee on Cancer classification","volume":"130","author":"Shah","year":"2102","journal-title":"Arch Ophthalmol"},{"key":"R9-18-20240828","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/ICO.0b013e3182523f61","article-title":"Interferon for ocular surface squamous neoplasia in 81 cases: Outcomes based on the American Joint Committee on Cancer classification","volume":"32","author":"Shields","year":"2013","journal-title":"Cornea"},{"key":"R10-18-20240828","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ophtha.2011.11.035","article-title":"Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction","volume":"119","author":"Kim","year":"2012","journal-title":"Ophthalmology"},{"key":"R11-18-20240828","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/bjo.2008.153197","article-title":"Topical interferon alpha 2b eyedrops for treatment of ocular surface squamous neoplasia: A dose comparison study","volume":"94","author":"Galor","year":"2010","journal-title":"Br J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1665_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:40:39Z","timestamp":1787845239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1665_20"}},"subtitle":["Comparative analysis of outcomes based on original tumor configuration"],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1665_20","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}